{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:48:03Z","timestamp":1770140883381,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T00:00:00Z","timestamp":1410393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100006047","name":"State Committee for Scientific Research","doi-asserted-by":"crossref","award":["2 P05F 036 29"],"award-info":[{"award-number":["2 P05F 036 29"]}],"id":[{"id":"10.13039\/501100006047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hyperprolactinaemia is suggested to be associated with metabolic and hormonal complications. No previous study has compared the effect of different dopamine agonists on plasma lipids, carbohydrate metabolism markers and cardiovascular risk factors in patients with elevated prolactin levels. The study included eight bromocriptine\u2010resistant women with prolactinoma (group 1) and twelve matched women with hyperprolactinaemia unrelated to prolactinoma (group 2). Group 1 was then treated with cabergoline, while group 2 with bromocriptine. Plasma lipids, glucose homeostasis markers and plasma levels of prolactin, insulin\u2010like growth factor\u20101 (IGF\u20101) and cardiovascular risk factors were assessed before and after 6\u00a0months of therapy. Both treatments normalized plasma prolactin levels. Cabergoline reduced triglycerides, 2\u2010hr post\u2010challenge plasma glucose, the homeostatic model assessment of insulin resistance (HOMA\u2010IR), and circulating levels of IGF\u20101, free fatty acids (FFA), uric acid, high\u2010sensitivity C\u2010reactive protein (hsCRP), homocysteine and fibrinogen, as well as increased HDL cholesterol and 25\u2010hydroxyvitamin D. With the exception of a reduction in HOMA\u2010IR, bromocriptine treatment produced no significant effect on the investigated biomarkers. Cabergoline was superior to bromocriptine in affecting 2\u2010hr post\u2010challenge plasma glucose levels, HOMA\u2010IR, as well as circulating levels of IGF\u20101, FFA, uric acid, hsCRP, homocysteine, fibrinogen and 25\u2010hydroxyvitamin D. Our results may suggest that cabergoline is superior to bromocriptine when it comes to affecting atherogenic dyslipidaemia, insulin sensitivity and circulating levels of cardiovascular risk factors in hyperprolactinaemic patients. These findings seem to support previous observations that cabergoline may be a better treatment for patients with elevated prolactin levels than bromocriptine.<\/jats:p>","DOI":"10.1111\/bcpt.12307","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T20:51:49Z","timestamp":1407963109000},"page":"251-256","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels"],"prefix":"10.1111","volume":"116","author":[{"given":"Robert","family":"Krysiak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology Medical University of Silesia Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogus\u0142aw","family":"Okopien","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology Medical University of Silesia Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1490187"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.150"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02469.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0277-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0495-z"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-0660-z"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00403.x"},{"key":"e_1_2_7_9_1","first-page":"254","article-title":"Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma","volume":"136","author":"Schmid C","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-1-33"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1470077"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12204"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-012-9857-y"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0064"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1154"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1697"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2009"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSOTT.S9575"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1833"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0022"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.151S017"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2012.06.014"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211795428858"},{"issue":"12","key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1301\/nr.2007.dec.S253-S259","article-title":"Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity","volume":"65","author":"Ridker PM","year":"2007","journal-title":"Nutr Rev"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.09.014"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363170-00005"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/86.5.1563S"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800885"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.112.967604"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcs240"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:28:1:101"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2007.06.004"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000095530"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2007.03.003"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2007.10.013"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12307","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:41:59Z","timestamp":1696401719000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,11]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/bcpt.12307"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12307","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,11]]},"assertion":[{"value":"2014-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}